Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Cost Realignment Program by Quarter
Cost Realignment Program — Cumulative costs attributable to Biopharma ($M) ($M)
Pfizer Cost Realignment Program: $3,800M in Q2 2026, up 40.7% from a year earlier. That is the highest of the 11 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note 3 — Restructuring Charges & Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost Realignment Program — Cumulative costs attributable to Biopharma ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 3,800 | +40.7% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 3,300 | +22.2% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,200 | +52.4% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 28, 2025 | 2,900 | +107.1% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 2,700 | +125.0% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 2,700 | +107.7% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,100 | +211.6% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 29, 2024 | 1,400 | – | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,200 | – | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,300 | – | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 674 | – | Form 10-K (filed 2024-02-22) ↗ |
Cite this data
StockData. (2026). Pfizer Cost Realignment Program ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/restruct-cum-realign-bio
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.